Healthcare
Boiron SA(BOIRF)
Live Price
Offline$31.90
+0.00% today
1Y Change
+11.93%
Window
Jun 25, 2025 β Jun 17, 2026
- Market Cap
- $470.00M
- Revenue Growth
- -1.2%
- EPS Growth
- -68.4%
- Dividend Yield
- 4.4%
Coverage: 246 bars Β· Jun 25, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Boiron SA (BOIRF) is a Healthcare stock with a market cap of $470.00M and listed on OTC. The stock last traded around $31.90 and up 11.9% across the available one-year price window (Jun 25, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of -1.2%, EPS growth of -68.4%, a dividend yield of 4.4%. What stands out right now is revenue -1.2%, EPS -68.4%, free cash flow -14.1% with operating margin 7.1% and ROIC 5.7%. The dividend matters to the case here, with a current yield around 4.4%. Valuation is more restrained than many high-expectation growth names at P/E 14.6 and price/sales 0.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines BOIRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.2% vs +7.6% peer median
Operating Margin
Below sector median
+7.1% vs +19.4% peer median
P/E
Below sector median
14.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Sep 18, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.2% and EPS is at -68.4%, with operating margin around 7.1%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Sep 18, 2025 | β | +0.0% | +0.0% | +0.0% |
2025 Apr 3, 2025 | β | +0.0% | +0.0% | +0.0% |
2024 Sep 19, 2024 | β | +0.0% | +0.0% | +0.0% |
Benchmark Edge
BOIRF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BOIRF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BOIRF Max Drawdown
-15.79%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for BOIRF and SPY.
Company Overview
Boiron SA
OTC
Boiron SA is a leading pharmaceutical company specializing in the production and distribution of homeopathic medicines, recognized as the world's largest manufacturer in this field. Founded in 1932 by twin brothers Jean and Henri Boiron, pharmacists with expertise in science and microbiology, it originated as the Central Homeopathic Laboratory of France in Paris and was formally incorporated as Laboratoires Boiron in 1967. Headquartered in Ste. Foy-lès-Lyon near Lyon, France, the company offers over 1,500 remedies, including mono-preparations, combination formulas, and popular over-the-counter products such as Oscillococcinum for flu relief, Arnicare for pain relief, Stodal for coughs, Arnigel, Camilia for teething, and Verrulia for warts. These are available in forms like tablets, drops, syrups, ointments, and gels, emphasizing low-risk, non-toxic options compliant with regulations including U.S. FDA standards and the Homeopathic Pharmacopoeia. Boiron SA operates in more than 59 countries across Europe, North America, South America, Africa, the Middle East, Asia, and Australia, with subsidiaries and production facilities worldwide. It supports scientific research, trains healthcare professionals, and holds a dominant position in the niche homeopathy market, generating significant revenue primarily from France while expanding internationally through strategic acquisitions like Dolisos in 2005.
- Leadership
- Ms. Anette Sofie Olsen
- Employees
- 2.5k
- Street Address
- 2, avenue de lβOuest Lyonnais, PO Box 1159 Sentrum
- Mailing
- Messimy, MI, 69510
- Region
- Messimy, MI, France
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 14.6
- EV/EBITDA
- 6.4
- Price/Sales
- 0.9
- Price/Book
- 1.2
Growth
- Revenue
- -1.2%
- EPS
- -68.4%
- Free Cash Flow
- -14.1%
Profitability
- Gross Margin
- 73.0%
- Operating Margin
- 7.1%
- Net Margin
- 6.5%
- ROE
- 8.6%
- ROIC
- 5.7%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 2.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.